Quantitative structure–pharmacokinetic relationships

Bibliography

• Oprea TI, Matter H. Integrating virtual screening in lead discovery. Curr Opin Chem Biol 2004;8(4):349-58
   PubMed Web of Science ®Google Scholar
• Schneider G, Fechner U. Computer-based de novo design of drug-like molecules. Nat Rev Drug Discov 2005;4(8):649-63
   PubMed Web of Science ®Google Scholar
• Karelson M. Molecular descriptors in QSAR/QSPR. John Wiley & Sons, New York; 2000
   Google Scholar
• Kier LB, Hall LH. Molecular connectivity in chemistry and drug research. Academic Press, Inc., New York; 1976
   Google Scholar
• Mager DE. Quantitative structure-pharmacokinetic/pharmacodynamic relationships. Adv Drug Deliv Rev 2006;58(12-13):1326-56
   PubMed Web of Science ®Google Scholar
• Geladi P, Kowalski BR. Partial least-squares regression – a tutorial. Anal Chim Acta 1986;185:1-17
   Web of Science ®Google Scholar
• Ripley BD. Pattern recognition and neural networks. Cambridge University Press, Cambridge; 1996
   Google Scholar
• Breiman L. Bagging predictors. Mach Learn 1996;24(2):123-40
   Web of Science ®Google Scholar
• Breiman L. Random forests. Mach Learn 2001;45(1):5-32
   Web of Science ®Google Scholar
• Sakiyama Y. The use of machine learning and nonlinear statistical tools for ADME prediction. Expert Opin Drug Metab Toxicol 2009;5(2):149-69
   PubMed Web of Science ®Google Scholar
• Vapnik V. The nature of statistical learning theory. Springer, New York; 1995
   Google Scholar
• Obrezanova O, Csanyi G, Gola JM, Gaussian processes: a method for automatic QSAR modeling of ADME properties. J Chem Inf Model 2007;47(5):1847-57
   PubMed Web of Science ®Google Scholar
• Cover TM, Hart PE. Nearest neighbor pattern classification. IEEE Trans Inf Theory 1967;13(1):21-7
   Web of Science ®Google Scholar
• Martinez MN, Amidon GL. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol 2002;42(6):620-43
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23(1-3):3-25
   Web of Science ®Google Scholar
• Hou T, Wang J. Structure-ADME relationship: still a long way to go? Expert Opin Drug Metab Toxicol 2008;4(6):759-70
   PubMed Web of Science ®Google Scholar
• Dressman JB, Amidon GL, Fleisher D. Absorption potential: estimating the fraction absorbed for orally administered compounds. J Pharm Sci 1985;74(5):588-9
   PubMed Web of Science ®Google Scholar
• Palm K, Stenberg P, Luthman K, Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm Res 1997;14(5):568-71
   PubMed Web of Science ®Google Scholar
• Grass GM, Sinko PJ. Effect of diverse datasets on the predictive capability of ADME models in drug discovery. Drug Discov Today 2001;6(12):S54-61
   PubMed Web of Science ®Google Scholar
• Hou T, Wang J, Zhang W, ADME evaluation in drug discovery. 7. Prediction of oral absorption by correlation and classification. J Chem Inf Model 2007;47(1):208-18
   PubMed Web of Science ®Google Scholar
• Watari N, Sugiyama Y, Kaneniwa N, Prediction of hepatic first-pass metabolism and plasma levels following intravenous and oral administration of barbiturates in the rabbit based on quantitative structure-pharmacokinetic relationships. J Pharmacokinet Biopharm 1988;16(3):279-301
   PubMedGoogle Scholar
• Bermejo M, Merino V, Garrigues TM, Validation of a biophysical drug absorption model by the PATQSAR system. J Pharm Sci 1999;88(4):398-405
   PubMed Web of Science ®Google Scholar
• Linnankoski J, Makela JM, Ranta VP, Computational prediction of oral drug absorption based on absorption rate constants in humans. J Med Chem 2006;49(12):3674-81
   PubMed Web of Science ®Google Scholar
• Deconinck E, Hancock T, Coomans D, Classification of drugs in absorption classes using the classification and regression trees (CART) methodology. J Pharm Biomed Anal 2005;39(1-2):91-103
   PubMed Web of Science ®Google Scholar
• Hou T, Wang J, Li Y. ADME evaluation in drug discovery. 8. The prediction of human intestinal absorption by a support vector machine. J Chem Inf Model 2007;47(6):2408-15
   PubMed Web of Science ®Google Scholar
• Turner JV, Maddalena DJ, Agatonovic-Kustrin S. Bioavailability prediction based on molecular structure for a diverse series of drugs. Pharm Res 2004;21(1):68-82
   PubMed Web of Science ®Google Scholar
• Jung E, Kim J, Kim M, Artificial neural network models for prediction of intestinal permeability of oligopeptides. BMC Bioinformatics 2007;8:245
   PubMed Web of Science ®Google Scholar
• Ghuman J, Zunszain PA, Petitpas I, Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol 2005;353(1):38-52
   PubMed Web of Science ®Google Scholar
• Obach RS, Lombardo F, Waters NJ. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos 2008;36(7):1385-405
   PubMed Web of Science ®Google Scholar
• van de Waterbeemd H, Smith DA, Jones BC. Lipophilicity in PK design: methyl, ethyl, futile. J Comput Aided Mol Des 2001;15(3):273-86
   PubMed Web of Science ®Google Scholar
• Toon S, Rowland M. Structure-pharmacokinetic relationships among the barbiturates in the rat. J Pharmacol Exp Ther 1983;225(3):752-63
   PubMed Web of Science ®Google Scholar
• Mager DE, Jusko WJ. Quantitative structure-pharmacokinetic/pharmacodynamic relationships of corticosteroids in man. J Pharm Sci 2002;91(11):2441-51
   PubMed Web of Science ®Google Scholar
• Gleeson MP. Plasma protein binding affinity and its relationship to molecular structure: an in-silico analysis. J Med Chem 2007;50(1):101-12
   PubMed Web of Science ®Google Scholar
• Klopman G, Stefan LR, Saiakhov RD. ADME evaluation. 2. A computer model for the prediction of intestinal absorption in humans. Eur J Pharm Sci 2002;17(4-5):253-63
   PubMed Web of Science ®Google Scholar
• Gleeson MP. Plasma protein binding affinity and its relationship to molecular structure: an in-silico analysis. J Med Chem 2007;50(1):101-12
   PubMed Web of Science ®Google Scholar
• Wang J, Krudy G, Xie XQ, Genetic algorithm-optimized QSPR models for bioavailability, protein binding, and urinary excretion. J Chem Inf Model 2006;46(6):2674-83
   PubMed Web of Science ®Google Scholar
• Yap CW, Chen YZ. Quantitative structure-pharmacokinetic relationships for drug distribution properties by using general regression neural network. J Pharm Sci 2005;94(1):153-68
   PubMed Web of Science ®Google Scholar
• Votano JR, Parham M, Hall LM, QSAR modeling of human serum protein binding with several modeling techniques utilizing structure-information representation. J Med Chem 2006;49(24):7169-81
   PubMed Web of Science ®Google Scholar
• Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 1999;27(11):1350-9
   PubMed Web of Science ®Google Scholar
• Gertz M, Kilford PJ, Houston JB, Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations. Drug Metab Dispos 2008;36(3):535-42
   PubMed Web of Science ®Google Scholar
• Austin RP, Barton P, Cockroft SL, The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos 2002;30(12):1497-503
   PubMed Web of Science ®Google Scholar
• Gao H, Yao L, Mathieu HW, In silico modeling of nonspecific binding to human liver microsomes. Drug Metab Dispos 2008;36(10):2130-5
   PubMed Web of Science ®Google Scholar
• Kilford PJ, Gertz M, Houston JB, Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data. Drug Metab Dispos 2008;36(7):1194-7
   PubMed Web of Science ®Google Scholar
• Oie S, Tozer TN. Effect of altered plasma protein binding on apparent volume of distribution. J Pharm Sci 1979;68(9):1203-5
   PubMed Web of Science ®Google Scholar
• Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 2005;94(6):1259-76
   PubMed Web of Science ®Google Scholar
• Lombardo F, Obach RS, Shalaeva MY, Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. J Med Chem 2002;45(13):2867-76
   PubMed Web of Science ®Google Scholar
• Lombardo F, Obach RS, Shalaeva MY, Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. J Med Chem 2004;47(5):1242-50
   PubMed Web of Science ®Google Scholar
• Sui X, Sun J, Li H, Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data. Eur J Med Chem 2009;44(11):4455-60
   PubMed Web of Science ®Google Scholar
• Gleeson MP, Waters NJ, Paine SW, In silico human and rat Vss quantitative structure-activity relationship models. J Med Chem 2006;49(6):1953-63
   PubMed Web of Science ®Google Scholar
• Lombardo F, Obach RS, Dicapua FM, A hybrid mixture discriminant analysis-random forest computational model for the prediction of volume of distribution of drugs in human. J Med Chem 2006;49(7):2262-7
   PubMed Web of Science ®Google Scholar
• Hinderling PH, Schmidlin O, Seydel JK. Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man. J Pharmacokinet Biopharm 1984;12(3):263-87
   PubMedGoogle Scholar
• Mayer JM, Hall SD, Rowland M. Relationship between lipophilicity and tubular reabsorption for a series of 5-alkyl-5-ethylbarbituric acids in the isolated perfused rat kidney preparation. J Pharm Sci 1988;77(4):359-64
   PubMed Web of Science ®Google Scholar
• Jones HM, Houston JB. Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations. Drug Metab Dispos 2004;32(9):973-82
   PubMed Web of Science ®Google Scholar
• Bursi R, de Gooyer ME, Grootenhuis A, (Q) SAR study on the metabolic stability of steroidal androgens. J Mol Graph Model 2001;19(6):552-6, 607-8
   PubMed Web of Science ®Google Scholar
• Jensen BF, Sorensen MD, Kissmeyer AM, Prediction of in vitro metabolic stability of calcitriol analogs by QSAR. J Comput Aided Mol Des 2003;17(12):849-59
   PubMed Web of Science ®Google Scholar
• Lee PH, Cucurull-Sanchez L, Lu J, Development of in silico models for human liver microsomal stability. J Comput Aided Mol Des 2007;21(12):665-73
   PubMed Web of Science ®Google Scholar
• Sakiyama Y, Yuki H, Moriya T, Predicting human liver microsomal stability with machine learning techniques. J Mol Graph Model 2008;26(6):907-15
   PubMed Web of Science ®Google Scholar
• Chang C, Duignan DB, Johnson KD, The development and validation of a computational model to predict rat liver microsomal clearance. J Pharm Sci 2009;98(8):2857-67
   PubMed Web of Science ®Google Scholar
• Schwaighofer A, Schroeter T, Mika S, A probabilistic approach to classifying metabolic stability. J Chem Inf Model 2008;48(4):785-96
   PubMed Web of Science ®Google Scholar
• Shen M, Xiao Y, Golbraikh A, Development and validation of k-nearest-neighbor QSPR models of metabolic stability of drug candidates. J Med Chem 2003;46(14):3013-20
   PubMed Web of Science ®Google Scholar
• Czodrowski P, Kriegl JM, Scheuerer S, Computational approaches to predict drug metabolism. Expert Opin Drug Metab Toxicol 2009;5(1):15-27
   PubMed Web of Science ®Google Scholar
• de Graaf C, Vermeulen NP, Feenstra KA. Cytochrome p450 in silico: an integrative modeling approach. J Med Chem 2005;48(8):2725-55
   PubMed Web of Science ®Google Scholar
• Wang YH, Li Y, Li YH, Modeling K-m values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism. Bioorg Med Chem Lett 2005;15(18):4076-84
   PubMed Web of Science ®Google Scholar
• Chohan KK, Paine SW, Mistry J, A rapid computational filter for cytochrome P450 1A2 inhibition potential of compound libraries. J Med Chem 2005;48(16):5154-61
   PubMed Web of Science ®Google Scholar
• Gleeson MP, Davis AM, Chohan KK, Generation of in-silico cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 inhibition QSAR models. J Comput Aided Mol Des 2007;21(10-11):559-73
   PubMed Web of Science ®Google Scholar
• Byvatov E, Baringhaus KH, Schneider G, A virtual screening filter for identification of cytochrome P4502C9 (CYP2C9) inhibitors. QSAR Comb Sci 2007;26(5):618-28
   Google Scholar
• Kriegl JM, Arnhold T, Beck B, A support vector machine approach to classify human cytochrome P450 3A4 inhibitors. J Comput Aided Mol Des 2005;19(3):189-201
   PubMed Web of Science ®Google Scholar
• Jensen BF, Vind C, Padkjaer SB, In silico prediction of cytochrome P450 2D6 and 3A4 inhibition using Gaussian kernel weighted k-nearest neighbor and extended connectivity fingerprints, including structural fragment analysis of inhibitors versus noninhibitors. J Med Chem 2007;50(3):501-11
   PubMed Web of Science ®Google Scholar
• Eitrich T, Kless A, Druska C, Classification of highly unbalanced CYP450 data of drugs using cost sensitive machine learning techniques. J Chem Inf Model 2007;47(1):92-103
   PubMed Web of Science ®Google Scholar
• O'Brien SE, de Groot MJ. Greater than the sum of its parts: combining models for useful ADMET prediction. J Med Chem 2005;48(4):1287-91
   PubMed Web of Science ®Google Scholar
• Hudelson MG, Ketkar NS, Holder LB, High confidence predictions of drug-drug interactions: predicting affinities for cytochrome P450 2C9 with multiple computational methods. J Med Chem 2008;51(3):648-54
   PubMed Web of Science ®Google Scholar
• Terfloth L, Bienfait B, Gasteiger J. Ligand-based models for the isoform specificity of cytochrome P450 3A4, 2D6, and 2C9 substrates. J Chem Inf Model 2007;47(4):1688-701
   PubMed Web of Science ®Google Scholar
• Ekins S, Bravi G, Binkley S, Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors. Drug Metab Dispos 2000;28(8):994-1002
   PubMed Web of Science ®Google Scholar
• Ekins S, Bravi G, Binkley S, Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. Pharmacogenetics 1999;9(4):477-89
   PubMedGoogle Scholar
• Ekins S, Bravi G, Wikel JH, Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther 1999;291(1):424-33
   PubMed Web of Science ®Google Scholar
• Ekins S, Bravi G, Binkley S, Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors. J Pharmacol Exp Ther 1999;290(1):429-38
   PubMed Web of Science ®Google Scholar
• Ekins S, Bravi G, Ring BJ, Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6. J Pharmacol Exp Ther 1999;288(1):21-9
   PubMed Web of Science ®Google Scholar
• Afzelius L, Zamora I, Masimirembwa CM, Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors. J Med Chem 2004;47(4):907-14
   PubMed Web of Science ®Google Scholar
• Afzelius L, Raubacher F, Karlen A, Structural analysis of CYP2C9 and CYP2C5 and an evaluation of commonly used molecular modeling techniques. Drug Metab Dispos 2004;32(11):1218-29
   PubMed Web of Science ®Google Scholar
• Sun H, Scott DO. Structure-based drug metabolism predictions for drug design. Chem Biol Drug Des 2010;75(1):3-17
   PubMed Web of Science ®Google Scholar
• Bazeley PS, Prithivi S, Struble CA, Synergistic use of compound properties and docking scores in neural network modeling of CYP2D6 binding: predicting affinity and conformational sampling. J Chem Inf Model 2006;46(6):2698-708
   PubMed Web of Science ®Google Scholar
• Xu C, Barchet TM, Mager DE. Quantitative structure-property relationships of camptothecins in humans. Cancer Chemother Pharmacol 2009;65(2):325-33
   Google Scholar
• Yap CW, Li ZR, Chen YZ. Quantitative structure-pharmacokinetic relationships for drug clearance by using statistical learning methods. J Mol Graph Model 2006;24(5):383-95
   PubMed Web of Science ®Google Scholar
• Dedrick R, Bischoff KB, Zaharko DS. Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother Rep 1970;54(2):95-101
   PubMedGoogle Scholar
• Wajima T, Yano Y, Fukumura K, Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles. J Pharm Sci 2004;93(7):1890-900
   PubMed Web of Science ®Google Scholar
• Winkler DA. Neural networks as robust tools in drug lead discovery and development. Mol Biotechnol 2004;27(2):139-68
   PubMed Web of Science ®Google Scholar
• Veng-Pedersen P, Modi NB. Application of neural networks to pharmacodynamics. J Pharm Sci 1993;82(9):918-26
   PubMed Web of Science ®Google Scholar
• Gobburu JV, Chen EP. Artificial neural networks as a novel approach to integrated pharmacokinetic-pharmacodynamic analysis. J Pharm Sci 1996;85(5):505-10
   PubMed Web of Science ®Google Scholar
• Yu LX, Amidon GL. A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm 1999;186(2):119-25
   PubMed Web of Science ®Google Scholar
• Jamei M, Marciniak S, Feng K, The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 2009;5(2):211-23
   PubMed Web of Science ®Google Scholar
• Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 2001;50(Suppl 1):S41-67
   PubMed Web of Science ®Google Scholar
• Willmann S, Schmitt W, Keldenich J, A physiological model for the estimation of the fraction dose absorbed in humans. J Med Chem 2004;47(16):4022-31
   PubMed Web of Science ®Google Scholar
• Usansky HH, Sinko PJ. Estimating human drug oral absorption kinetics from Caco-2 permeability using an absorption-disposition model: model development and evaluation and derivation of analytical solutions for k(a) and F(a). J Pharmacol Exp Ther 2005;314(1):391-9
   PubMed Web of Science ®Google Scholar
• Fliszar KA, Hill BT, Foster N. Predicting human drug pharmacokinetics from in vitro permeability using an absorption-disposition model. J Pharm Sci 2007;96(8):2161-70
   PubMed Web of Science ®Google Scholar
• Peters SA. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis. Clin Pharmacokinet 2008;47(4):261-75
   PubMed Web of Science ®Google Scholar
• Blakey GE, Nestorov IA, Arundel PA, Quantitative structure-pharmacokinetics relationships: I. Development of a whole-body physiologically based model to characterize changes in pharmacokinetics across a homologous series of barbiturates in the rat. J Pharmacokinet Biopharm 1997;25(3):277-312
   PubMedGoogle Scholar
• Nestorov I, Aarons L, Rowland M. Quantitative structure-pharmacokinetics relationships: II. A mechanistically based model to evaluate the relationship between tissue distribution parameters and compound lipophilicity. J Pharmacokinet Biopharm 1998;26(5):521-45
   PubMedGoogle Scholar
• Kamgang E, Peyret T, Krishnan K. An integrated QSPR-PBPK modelling approach for in vitro-in vivo extrapolation of pharmacokinetics in rats. SAR QSAR Environ Res 2008;19(7-8):669-80
   PubMed Web of Science ®Google Scholar
• Poulin P, Theil FP. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci 2000;89(1):16-35
   PubMed Web of Science ®Google Scholar
• Poulin P, Schoenlein K, Theil FP. Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. J Pharm Sci 2001;90(4):436-47
   PubMed Web of Science ®Google Scholar
• Luttringer O, Theil FP, Poulin P, Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans. J Pharm Sci 2003;92(10):1990-2007
   PubMed Web of Science ®Google Scholar
• Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci 2002;91(5):1358-70
   PubMed Web of Science ®Google Scholar
• Jones HM, Parrott N, Jorga K, A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 2006;45(5):511-42
   PubMed Web of Science ®Google Scholar
• Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 2006;95(6):1238-57
   PubMed Web of Science ®Google Scholar
• Poulin P, Theil FP. Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods. J Pharm Sci 2009;98(12):4941-61
   PubMed Web of Science ®Google Scholar
• Berezhkovskiy LM. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J Pharm Sci 2004;93(6):1628-40
   PubMed Web of Science ®Google Scholar
• Fenneteau F, Poulin P, Nekka F. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. J Pharm Sci 2010;99(1):486-514
   PubMed Web of Science ®Google Scholar
• Almond LM, Yang J, Jamei M, Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. Curr Drug Metab 2009;10(4):420-32
   PubMed Web of Science ®Google Scholar
• Johnson TN, Boussery K, Rowland-Yeo K, A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet 2010;49(3):189-206
   PubMed Web of Science ®Google Scholar
• Johnson TN, Thomson M. Intestinal metabolism and transport of drugs in children: the effects of age and disease. J Pediatr Gastroenterol Nutr 2008;47(1):3-10
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kusuhara H, Maeda K, Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 2009;328(2):652-62
   PubMed Web of Science ®Google Scholar
• Park S, Kim SH, Ropella GE, Tracing multiscale mechanisms of drug disposition in normal and diseased livers. J Pharmacol Exp Ther 2010;334(1):124-36
   PubMed Web of Science ®Google Scholar
• Yan L, Sheihk-Bahaei S, Park S, Predictions of hepatic disposition properties using a mechanistically realistic, physiologically based model. Drug Metab Dispos 2008;36(4):759-68
   PubMed Web of Science ®Google Scholar
• Walker JR, Brown K, Rohatagi S, Quantitative structure-property relationships modeling to predict in vitro and in vivo binding of drugs to the bile sequestrant, colesevelam (Welchol). J Clin Pharmacol 2009;49(10):1185-95
   PubMed Web of Science ®Google Scholar
• Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008;84(5):548-58
   PubMed Web of Science ®Google Scholar
• Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 2001;28(6):507-32
   PubMed Web of Science ®Google Scholar
• Urva SR, Yang VC, Balthasar JP. Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody. J Pharm Sci 2010;99(3):1582-600
   PubMed Web of Science ®Google Scholar
• Balogh L, Nigavekar SS, Nair BM, Significant effect of size on the in vivo biodistribution of gold composite nanodevices in mouse tumor models. Nanomedicine 2007;3(4):281-96
   PubMed Web of Science ®Google Scholar
• Nigavekar SS, Sung LY, Llanes M, 3H dendrimer nanoparticle organ/tumor distribution. Pharm Res 2004;21(3):476-83
   PubMed Web of Science ®Google Scholar
• Mager DE, Pyszczynski NA, Jusko WJ. Integrated QSPR–pharmacodynamic model of genomic effects of several corticosteroids. J Pharm Sci 2003;92(4):881-9
   PubMed Web of Science ®Google Scholar
• Arrell DK, Terzic A. Network systems biology for drug discovery. Clin Pharmacol Ther 2010;88(1):120-5
   PubMed Web of Science ®Google Scholar
• Berger SI, Iyengar R. Network analyses in systems pharmacology. Bioinformatics 2009;25(19):2466-72
   PubMed Web of Science ®Google Scholar